drugset / Trial / NCT00582855

Effect of AQW051 in Patients With Memory Impairment

NCT00582855 ↗

Phase 2 Terminated 54 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will investigate AQW051 in patients with either mild Alzheimer's disease or amnestic mild cognitive impairment. The effect on cognitive impairment will be measure using validated computerized tests which measure cognitive function. This study will also explore the safety and tolerability of AQW051 in these patients.

Timeline

Start
2007-12
Primary completion
2009-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject AQW051 Small molecule — —